Insulet | PODD - Operating Expenses


Insulet reported $672M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Abbott USD 11.66B 1.2B Sep/2026
Align Technology USD 864.87M 2.84M Jun/2026
AtriCure USD 143.94M 3.22M Jun/2026
Baxter International USD 2.68B 3.36B Jun/2026
Becton, Dickinson and Co. USD 24.42B 283M Jun/2026
Boston Scientific USD 4.2B 49M Jun/2026
Cardinal Health USD 62.86B 65.69B Jun/2026
Cooper Companies USD 844.2M 268.3M Jun/2026
Dexcom USD 990.1M 53.5M Jun/2026
Edwards Lifesciences USD 1.22B 87.6M Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Globus Medical USD 835.58M 239.73M Jun/2026
ICU Medical USD 491.25M 8.59M Jun/2026
Inogen USD 49.14M 665K Sep/2024
Insulet USD 672M 32.3M Jun/2026
Integra LifeSciences USD 368.53M 674.84M Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Medtronic USD 7.92B 203M Jun/2026
Merit Medical Systems USD 358.44M 20.72M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Solventum Corp USD 4.8B 169M Jun/2026
Stryker USD 4.8B 118M Jun/2026
Tandem Diabetes Care USD 268.35M 3.7M Jun/2026
Teleflex USD 2.9B 179.9M Jun/2026
West Pharmaceutical Services USD 2.99B 200K Jun/2026
Zimmer Biomet Holdings USD 1.83B 140.7M Jun/2026